Literature DB >> 31230257

Community-acquired serious bacterial infections in the first 90 days of life: a revisit in the era of multi-drug-resistant organisms.

Dawood Yusef1,2,3, Tamara Jahmani4,5,6, Sajeda Kailani4,5,6, Rawan Al-Rawi4,5,6, Wasim Khasawneh4,5,6, Miral Almomani4,5,6.   

Abstract

BACKGROUND: Infants in the first 90 days of life are more prone to develop serious bacterial infections (SBIs). Multi-drug-resistant organisms (MDROs) are emerging as important pathogens causing SBIs. We reviewed the epidemiology of SBIs in infants 0-90 days old and compared the clinical features, laboratory values and final outcome for SBIs due to MDROs vs. non-MDROs.
METHODS: Episodes of culture-proven SBIs (bacteremia, urinary tract infections, or meningitis) with age at onset of 0-90 days during a 7-year period were retrospectively reviewed. Health care-associated infections were excluded. We collected demographics, clinical features, and laboratory and microbiology data. We compared clinical characteristics, laboratory data, microbiologic results and final outcome for SBIs due to MDROs vs. non-MDROs.
RESULTS: Ninety-four episodes (88 patients) including bacteremia (42.6%), urinary tract infections (54.3%) and meningitis (3.1%) were caused by Gram-negative bacteria (67%), and Gram-positive bacteria (33%). Escherichia coli, Klebsiella pneumoniae and GBS were the most common causes. MDROs caused SBIs in 39 patients (44.3%). SBIs due to MDROs were associated with more delay in providing targeted antimicrobial therapy compared to non-MDROs (74.4% vs. 0%, P ≤ 0.001), but no difference in case-fatality rate (12.8% vs. 12.2%, P = 1.0). Clinical features or basic laboratory values were not statistically different between the two groups.
CONCLUSIONS: The bacteriology of SBIs in the first 90 days of life is changing to include more MDROs, which causes more delay in providing targeted antimicrobial therapy. Awareness of the local epidemiology is crucial to ensure appropriate antibiotics are provided in a timely manner.

Entities:  

Keywords:  Multi-drug-resistance organisms; Neonates; Serious bacterial infections; Young infants

Year:  2019        PMID: 31230257     DOI: 10.1007/s12519-019-00276-w

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  23 in total

1.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

2.  Changing epidemiology of bacteremia in infants aged 1 week to 3 months.

Authors:  Tara L Greenhow; Yun-Yi Hung; Arnd M Herz
Journal:  Pediatrics       Date:  2012-02-27       Impact factor: 7.124

3.  Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998-2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-03-22       Impact factor: 17.586

4.  Clinical characteristics and epidemiology of sepsis in the neonatal intensive care unit in the era of multi-drug resistant organisms: A retrospective review.

Authors:  Dawood Yusef; Tala Shalakhti; Samah Awad; Hana'a Algharaibeh; Wasim Khasawneh
Journal:  Pediatr Neonatol       Date:  2017-06-09       Impact factor: 2.083

5.  Empiric Antibiotic Use and Susceptibility in Infants With Bacterial Infections: A Multicenter Retrospective Cohort Study.

Authors:  Elana A Feldman; Russell J McCulloh; Angela L Myers; Paul L Aronson; Mark I Neuman; Miranda C Bradford; Elizabeth R Alpern; Frances Balamuth; Mercedes M Blackstone; Whitney L Browning; Katie Hayes; Rosalynne Korman; Rianna C Leazer; Lise E Nigrovic; Richard Marble; Emily Roben; Derek J Williams; Joel S Tieder
Journal:  Hosp Pediatr       Date:  2017-07-20

6.  Epidemiology of bacteremia in febrile infants in the United States.

Authors:  Eric Biondi; Rianna Evans; Matthew Mischler; Michael Bendel-Stenzel; Sara Horstmann; Vivan Lee; Jean Aldag; Francis Gigliotti
Journal:  Pediatrics       Date:  2013-11-11       Impact factor: 7.124

7.  Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains.

Authors:  Jung-Jr Ye; Ching-Tai Huang; Shian-Sen Shie; Po-Yen Huang; Lin-Hui Su; Cheng-Hsun Chiu; Hsieh-Shong Leu; Ping-Cherng Chiang
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

8.  Serious bacterial infections in febrile infants younger than 90 days of age: the importance of ampicillin-resistant pathogens.

Authors:  Carrie L Byington; Kristine K Rittichier; Kathlene E Bassett; Heidi Castillo; Tiffany S Glasgow; Judy Daly; Andrew T Pavia
Journal:  Pediatrics       Date:  2003-05       Impact factor: 7.124

9.  Risk of resistant infections with Enterobacteriaceae in hospitalized neonates.

Authors:  Nalini Singh; Kantilal M Patel; Marie-Michèle Léger; Billie Short; Bruce M Sprague; Nnenna Kalu; Joseph M Campos
Journal:  Pediatr Infect Dis J       Date:  2002-11       Impact factor: 2.129

10.  Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections.

Authors:  Deborah A Levine; Shari L Platt; Peter S Dayan; Charles G Macias; Joseph J Zorc; William Krief; Jeffrey Schor; David Bank; Nancy Fefferman; Kathy N Shaw; Nathan Kuppermann
Journal:  Pediatrics       Date:  2004-06       Impact factor: 7.124

View more
  4 in total

1.  Antimicrobial Resistance and Resistance Determinant Insights into Multi-Drug Resistant Gram-Negative Bacteria Isolates from Paediatric Patients in China.

Authors:  Sandip Patil; Hongyu Chen; Xiaoli Zhang; Ma Lian; Pei-Gen Ren; Feiqiu Wen
Journal:  Infect Drug Resist       Date:  2019-11-22       Impact factor: 4.003

2.  Effect of a Short-Time Probiotic Supplementation on the Abundance of the Main Constituents of the Gut Microbiota of Term Newborns Delivered by Cesarean Section-A Randomized, Prospective, Controlled Clinical Trial.

Authors:  Joanna Hurkala; Ryszard Lauterbach; Renata Radziszewska; Magdalena Strus; Piotr Heczko
Journal:  Nutrients       Date:  2020-10-14       Impact factor: 5.717

3.  Prevalence and risk factors associated with multi-drug resistant organisms (MDRO) carriage among pediatric patients at the time of admission in a tertiary care hospital of a developing country. A cross-sectional study.

Authors:  Sonia Qureshi; Noshi Maria; Mohammad Zeeshan; Seema Irfan; Farah Naz Qamar
Journal:  BMC Infect Dis       Date:  2021-06-09       Impact factor: 3.090

Review 4.  Therapeutic Options and Outcomes for the Treatment of Neonates and Preterms with Gram-Negative Multidrug-Resistant Bacteria: A Systematic Review.

Authors:  Lorenzo Chiusaroli; Cecilia Liberati; Maria Caseti; Luigi Rulli; Elisa Barbieri; Carlo Giaquinto; Daniele Donà
Journal:  Antibiotics (Basel)       Date:  2022-08-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.